270 related articles for article (PubMed ID: 28545721)
1. Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data.
Trotter CL; Lingani C; Fernandez K; Cooper LV; Bita A; Tevi-Benissan C; Ronveaux O; Préziosi MP; Stuart JM
Lancet Infect Dis; 2017 Aug; 17(8):867-872. PubMed ID: 28545721
[TBL] [Abstract][Full Text] [Related]
2. Response thresholds for epidemic meningitis in sub-Saharan Africa following the introduction of MenAfriVac®.
Trotter CL; Cibrelus L; Fernandez K; Lingani C; Ronveaux O; Stuart JM
Vaccine; 2015 Nov; 33(46):6212-7. PubMed ID: 26463444
[TBL] [Abstract][Full Text] [Related]
3. Meningococcal Meningitis Surveillance in the African Meningitis Belt, 2004-2013.
Lingani C; Bergeron-Caron C; Stuart JM; Fernandez K; Djingarey MH; Ronveaux O; Schnitzler JC; Perea WA
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S410-5. PubMed ID: 26553668
[TBL] [Abstract][Full Text] [Related]
4. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.
Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA
Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241
[TBL] [Abstract][Full Text] [Related]
5. Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.
Djingarey MH; Diomandé FV; Barry R; Kandolo D; Shirehwa F; Lingani C; Novak RT; Tevi-Benissan C; Perea W; Preziosi MP; LaForce FM
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S434-41. PubMed ID: 26553672
[TBL] [Abstract][Full Text] [Related]
6. Status of the Rollout of the Meningococcal Serogroup A Conjugate Vaccine in African Meningitis Belt Countries in 2018.
Bwaka A; Bita A; Lingani C; Fernandez K; Durupt A; Mwenda JM; Mihigo R; Djingarey MH; Ronveaux O; Preziosi MP
J Infect Dis; 2019 Oct; 220(220 Suppl 4):S140-S147. PubMed ID: 31671448
[TBL] [Abstract][Full Text] [Related]
7. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].
Daugla DM; Gami JP; Gamougam K; Naibei N; Mbainadji L; Narbé M; Toralta J; Kodbesse B; Ngadoua C; Coldiron ME; Fermon F; Page AL; Djingarey MH; Hugonnet S; Harrison OB; Rebbetts LS; Tekletsion Y; Watkins ER; Hill D; Caugant DA; Chandramohan D; Hassan-King M; Manigart O; Nascimento M; Woukeu A; Trotter C; Stuart JM; Maiden M; Greenwood BM
Lancet; 2014 Jan; 383(9911):40-47. PubMed ID: 24035220
[TBL] [Abstract][Full Text] [Related]
8. The Diversity of Meningococcal Carriage Across the African Meningitis Belt and the Impact of Vaccination With a Group A Meningococcal Conjugate Vaccine.
MenAfriCar consortium
J Infect Dis; 2015 Oct; 212(8):1298-307. PubMed ID: 25858956
[TBL] [Abstract][Full Text] [Related]
9. Four years of case-based surveillance of meningitis following the introduction of MenAfriVac in Moissala, Chad: lessons learned.
Page AL; Coldiron ME; Gamougam K; Acyl MA; Tamadji M; Lastrucci C; Hurtado N; Tehoua FC; Fermon F; Caugant DA; Porten K
Trop Med Int Health; 2017 Dec; 22(12):1561-1568. PubMed ID: 28992391
[TBL] [Abstract][Full Text] [Related]
10. Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt.
Karachaliou A; Conlan AJ; Preziosi MP; Trotter CL
Clin Infect Dis; 2015 Nov; 61 Suppl 5(Suppl 5):S594-600. PubMed ID: 26553693
[TBL] [Abstract][Full Text] [Related]
11. Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination.
Collard JM; Issaka B; Zaneidou M; Hugonnet S; Nicolas P; Taha MK; Greenwood B; Jusot JF
BMC Infect Dis; 2013 Dec; 13():576. PubMed ID: 24313998
[TBL] [Abstract][Full Text] [Related]
12. Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM).
Frasch CE; Preziosi MP; LaForce FM
Hum Vaccin Immunother; 2012 Jun; 8(6):715-24. PubMed ID: 22495119
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt.
Kuznik A; Iliyasu G; Lamorde M; Mahmud M; Musa BM; Nashabaru I; Obaro S; Mohammed I; Habib AG
PLoS One; 2017; 12(11):e0188595. PubMed ID: 29190699
[TBL] [Abstract][Full Text] [Related]
14. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.
Xie O; Pollard AJ; Mueller JE; Norheim G
Vaccine; 2013 Jun; 31(27):2852-61. PubMed ID: 23623866
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of meningitis surveillance before introduction of serogroup a meningococcal conjugate vaccine - Burkina Faso and Mali.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1025-8. PubMed ID: 23254257
[TBL] [Abstract][Full Text] [Related]
16. Emergency vaccination against epidemic meningitis in Ghana: implications for the control of meningococcal disease in West Africa.
Woods CW; Armstrong G; Sackey SO; Tetteh C; Bugri S; Perkins BA; Rosenstein NE
Lancet; 2000 Jan; 355(9197):30-3. PubMed ID: 10615888
[TBL] [Abstract][Full Text] [Related]
17. [Meningococcal meningitis epidemics in sub-Saharan Africa and the meningococcal A conjugate vaccine].
Nicolas P
Med Sante Trop; 2012; 22(3):246-58. PubMed ID: 23186941
[TBL] [Abstract][Full Text] [Related]
18. Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials.
White M; Idoko O; Sow S; Diallo A; Kampmann B; Borrow R; Trotter C
Lancet Infect Dis; 2019 Mar; 19(3):327-336. PubMed ID: 30745277
[TBL] [Abstract][Full Text] [Related]
19. Emergence and control of epidemic meningococcal meningitis in sub-Saharan Africa.
Mohammed I; Iliyasu G; Habib AG
Pathog Glob Health; 2017 Feb; 111(1):1-6. PubMed ID: 28081671
[TBL] [Abstract][Full Text] [Related]
20. Neisseria meningitidis Serogroup W Meningitis Epidemic in Togo, 2016.
Mounkoro D; Nikiema CS; Maman I; Sakandé S; Bozio CH; Tall H; Sadji AY; Njanpop-Lafourcade BM; Sibabe A; Landoh DE; Abodji EO; Kodjo A; Tamekloe TA; Essoh TA; Maba DW; Gessner BD; Moïsi JC
J Infect Dis; 2019 Oct; 220(220 Suppl 4):S216-S224. PubMed ID: 31671438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
